Cardioprotective mechanisms of novel noncoding RNA in myocardial infarction
新型非编码RNA对心肌梗死的心脏保护机制
基本信息
- 批准号:10660164
- 负责人:
- 金额:$ 64.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-01 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:Acute myocardial infarctionAdoptive TransferAntisense OligonucleotidesAttentionBindingBiodistributionBiologicalBiological AvailabilityCardiotonic AgentsCaseinsCell NucleusCell SurvivalCell TherapyCellsChemicalsChronicDataDevelopmentDichloromethylene DiphosphonateDiseaseDuchenne muscular dystrophyEFRACFDA approvedGatekeepingGene ExpressionGenesHeartHeart DiseasesHeart failureHuman MilkIn VitroInfarctionInflammatoryInjuryInterleukin-10IntravenousIschemiaLeftLinkMacrophageMeasuresMediatingMediatorMessenger RNAMilk ProteinsModelingMusMyocardial InfarctionNecrosisNuclear Pore Complex ProteinsNucleotidesOralOral AdministrationOutcomePathway interactionsPeptidesPharmaceutical PreparationsPropertyRNARationalizationReperfusion TherapyRoleSmall Interfering RNATestingThinkingTissuesTransplantationUntranslated RNAWorkagedaptamercardioprotectioncytokinedosageexosomeextracellular vesiclesin vivoinsightmouse modelmutantnew chemical entitynovelparacrinepreservationprototyperegenerative cellregenerative therapytranscriptomicstranslational potential
项目摘要
PROJECT SUMMARY/ABSTRACT
This proposal seeks to understand the cardioprotective effects of a new noncoding RNA (ncRNA) entity, TY4,
that is bioinspired by the contents of exosomes. Our focus is on one class of small ncRNA, not previously
recognized as particularly relevant to cardiac disease. Y RNAs captured our attention because molecules
encoded by the YRNA4 gene are exceptionally plentiful in exosomes secreted by cardiosphere-derived cells.
The predominant such ncRNA, EV-YF1, has salutary properties when delivered on its own: EV-YF1 increases
IL-10 secretion, is cardioprotective and anti-hypertrophic. Here we present preliminary data on TY4, a new
chemical entity (NCE) bioinspired by EV-YF1. TY4 exerts global transcriptomic changes involving inflammatory
and fibrotic pathways, and exerts disease-modifying bioactivity in murine models of heart failure with preserved
ejection fraction, Duchenne muscular dystrophy, and MI. Remarkably, TY4, when formulated with the breast milk
protein casein, works orally in all three models. In terms of mechanism, preliminary data show that TY4 binds to
TPR, a nuclear pore complex protein that acts as a gatekeeper for messenger RNA export from the nucleus. We
have also found that macrophage depletion abrogates TY4-mediated cardioprotection. As a small chemically-
modified mutant NCE, TY4 has key features desirable in a synthetic RNA drug. But other RNA drugs, whether
FDA-approved or in development, all have known mechanisms of action: they are antisense oligos, small
interfering RNAs, aptamers, or miR-modifiers. TY4 fits into none of those classes and thus is the prototype for a
new class of RNA drugs. The focus here is on understanding the mechanism whereby TY4 limits infarct size.
We will test the following mechanistic hypothesis: TY4 is cardioprotective against MI by binding to TPR and
altering gene expression in target cells (and specifically, in macrophages). We will pursue the following Aims: 1:
Investigate the mechanism(s) whereby TY4 alters gene expression in macrophages. Sub-aims seek to
identify TY4 binding partners, characterize the transcriptomic changes induced by TY4, and prioritize biological
targets for further interrogation. 2: Optimize in vivo efficacy of oral TY4 in murine MI. Sub-aims seek to
optimize the dosage paradigm for oral TY4 in acute MI, measure biodistribution of TY4 after oral delivery in mice
pre- and post- acute MI, determine the window of opportunity for TY4 efficacy post-MI in acute MI, test TY4
cardioprotective efficacy in aged mice, and characterize the effects of optimized oral TY4 delivery in a chronic
MI model. 3: Test whether macrophages are necessary and sufficient to explain TY4 efficacy in acute MI.
Sub-aims seek to compare MI outcomes +/- TY4 with and without prior macrophage depletion, probe the relative
roles of tissue-resident versus circulating macrophages, and determine whether post-MI adoptive transfer of ex
vivo TY4-conditioned macrophages reduces infarct size in macrophage-depleted mice. While highly mechanistic,
our proposal, focusing on a synthetic ncRNA NCE bioinspired by exosomal cargo, also offers translational value
in its development of a novel cardioprotective agent that is effective even when given after reperfusion.
项目总结/摘要
该提案旨在了解一种新的非编码RNA(ncRNA)实体TY 4的心脏保护作用,
它是由外来体的内容物所启发的。我们的重点是一类小的ncRNA,而不是以前
被认为与心脏病特别相关。Y RNA吸引了我们的注意力,
由YRNA 4基因编码的外泌体在由心球来源的细胞分泌的外泌体中异常丰富。
主要的这种ncRNA,EV-YF 1,在其自身递送时具有有益的性质:EV-YF 1增加
IL-10分泌,具有心脏保护和抗肥大作用。在这里,我们提出了TY 4的初步数据,一个新的
由EV-YF 1生物启发的化学实体(NCE)。TY 4发挥涉及炎症的整体转录组学变化
和纤维化途径,并在心力衰竭的小鼠模型中发挥疾病修饰生物活性,
射血分数、Duchenne肌营养不良和MI。值得注意的是,TY 4与母乳一起配制时,
蛋白质酪蛋白,在所有三种模型中口服起作用。在机制方面,初步数据显示TY 4结合至
TPR是一种核孔复合物蛋白,作为信使RNA从细胞核输出的看门人。我们
还发现巨噬细胞消耗消除TY 4介导的心脏保护。作为一个小的化学-
修饰的突变体NCE,TY 4具有合成RNA药物中所需的关键特征。但是其他RNA药物,
FDA批准的或正在开发的,都有已知的作用机制:它们是反义寡核苷酸,小
干扰RNA、适体或miR-修饰剂。TY 4不适合这些类,因此是
新型RNA药物这里的重点是了解TY 4限制梗死面积的机制。
我们将检验以下机制假设:TY 4通过与TPR结合而对MI具有心脏保护作用,
改变靶细胞(特别是巨噬细胞)中的基因表达。我们将追求以下目标:1:
研究TY 4改变巨噬细胞基因表达的机制。子目标旨在
鉴定TY 4结合配偶体,表征TY 4诱导的转录组学变化,
进一步审讯的目标2:优化口服TY 4在鼠MI中的体内功效。子目标旨在
优化TY 4在急性MI中的口服剂量模式,测量口服递送后TY 4在小鼠中的生物分布
急性MI前和后,确定TY 4在急性MI中MI后疗效的机会窗口,试验TY 4
在老年小鼠中的心脏保护功效,并表征优化的口服TY 4递送在老年小鼠中的作用。
MI模型。3:测试巨噬细胞是否是解释TY 4在急性MI中的功效所必需的和充分的。
子目标旨在比较MI结局+/-TY 4伴和不伴既往巨噬细胞耗竭,探索相对
组织驻留与循环巨噬细胞的作用,并确定是否MI后过继转移的前
体内TY 4-调节的巨噬细胞减少巨噬细胞耗尽小鼠的梗死面积。虽然高度机械化,
我们的建议,集中在一个合成的ncRNA NCE生物启发外泌体货物,也提供了翻译价值
在其开发一种新的心脏保护剂,即使在再灌注后给予也是有效的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EDUARDO MARBAN其他文献
EDUARDO MARBAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EDUARDO MARBAN', 18)}}的其他基金
Exosome Therapeutics to Dissect HFpEF Mechanisms
外泌体疗法剖析 HFpEF 机制
- 批准号:
10296255 - 财政年份:2021
- 资助金额:
$ 64.13万 - 项目类别:
Exosome Therapeutics to Dissect HFpEF Mechanisms
外泌体疗法剖析 HFpEF 机制
- 批准号:
10657415 - 财政年份:2021
- 资助金额:
$ 64.13万 - 项目类别:
Exosome Therapeutics to Dissect HFpEF Mechanisms
外泌体疗法剖析 HFpEF 机制
- 批准号:
10427452 - 财政年份:2021
- 资助金额:
$ 64.13万 - 项目类别:
Cardioprotective mechanisms of cell therapy for myocardial infarction
细胞治疗心肌梗死的心脏保护机制
- 批准号:
9906252 - 财政年份:2017
- 资助金额:
$ 64.13万 - 项目类别:
Exosome-mediated cardioprotection and regeneration
外泌体介导的心脏保护和再生
- 批准号:
8759304 - 财政年份:2014
- 资助金额:
$ 64.13万 - 项目类别:
Exosome-mediated cardioprotection and regeneration
外泌体介导的心脏保护和再生
- 批准号:
8890879 - 财政年份:2014
- 资助金额:
$ 64.13万 - 项目类别:
Exosome-mediated cardioprotection and regeneration
外泌体介导的心脏保护和再生
- 批准号:
9047307 - 财政年份:2014
- 资助金额:
$ 64.13万 - 项目类别:
Electrophysiology and Cell Biology of Cardiac Stem Cells
心脏干细胞的电生理学和细胞生物学
- 批准号:
7391523 - 财政年份:2006
- 资助金额:
$ 64.13万 - 项目类别:
Dedifferentiation of cardiomyocytes into cardiac progenitor cells
心肌细胞去分化为心脏祖细胞
- 批准号:
8436173 - 财政年份:2006
- 资助金额:
$ 64.13万 - 项目类别:
Dedifferentiation of cardiomyocytes into cardiac progenitor cells
心肌细胞去分化为心脏祖细胞
- 批准号:
8039709 - 财政年份:2006
- 资助金额:
$ 64.13万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 64.13万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 64.13万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 64.13万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 64.13万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 64.13万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 64.13万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 64.13万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 64.13万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 64.13万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 64.13万 - 项目类别: